Lisdexamfetamine Brand names: Vyvanse, Arynta

What is lisdexamfetamine used for?

From the label: indications and usage

VYVANSE ® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies (14.1) ]. Moderate to severe binge eating disorder (BED) in adults [see Clinical Studies (14.2) ]. […]

Conditions named in the indications of lisdexamfetamine's FDA labels, with every medicine labeled for each:

• ADHD
• Binge eating disorder

FDA pharmacologic class: Central Nervous System Stimulant.

What does the patient leaflet for lisdexamfetamine say first?

The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.

From the patient leaflet: What is the most important information I should know about VYVANSE?

VYVANSE may cause serious side effects, including: Abuse, misuse, and addiction. VYVANSE has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of VYVANSE, other amphetamine containing medicines, and methylphenidate containing medicines, can lead to overdose and death. The risk of overdose and death is increased with higher doses of VYVANSE or when it is used in ways that are not approved, such as snorting or injection. Your healthcare provider should check you or your child's risk for abuse, misuse, and addiction before starting treatment with VYVANSE and will monitor you or your child during treatment. VYVANSE may lead to physical dependence after prolonged use, even if taken as directed by your healthcare provider. Do not give VYVANSE to anyone else. See " What is VYVANSE? " for more information. Keep VYVANSE in a safe place and properly dispose of any unused medicine. See " How should I store VYVANSE? " for more information. Tell your healthcare provider if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs. Risks for people with serious heart disease. Sudden death has happened in people who have heart defects or other serious heart disease. Your healthcare provider should check you or your child carefully for heart problems before starting treatment with VYVANSE. Tell your healthcare provider if you or your child have any heart problems, heart disease, or heart defects. Call your healthcare provider right away or go to the nearest hospital emergency room right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with VYVANSE. Increased blood pressure and heart rate. […]

From the patient leaflet: How should I store VYVANSE?

Store VYVANSE in a safe place (like a locked cabinet) at room temperature between 68°F to 77°F (20°C to 25°C). Keep the container tightly closed and protect VYVANSE from light. Dispose of remaining, unused, or expired VYVANSE by a medicine take-back program at a U.S. Drug Enforcement Administration (DEA) authorized collection site. If no take-back program or DEA authorized collector is available, mix VYVANSE with an undesirable, nontoxic substance such as dirt, cat litter, or used coffee grounds to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and throw away VYVANSE in the household trash. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines. Keep VYVANSE and all medicines out of the reach of children.

Is there a generic for lisdexamfetamine (Vyvanse)?

The FDA approved the first generic lisdexamfetamine on August 25, 2023. 22 generic applications are approved; 22 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.

FDA's NDC Directory lists lisdexamfetamine from 19 labelers under a generic (ANDA) application and from 2 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.

The Orange Book lists no patent for Vyvanse capsules; a patent listed only for Arynta oral solution runs to August 30, 2040. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

What do pharmacies pay for lisdexamfetamine (Vyvanse)?

In CMS's NADAC survey of October 7, 2026, pharmacies paid $2.44 per Lisdexamfetamine 20 mg capsule, down 32% from $3.57 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.

Is lisdexamfetamine in shortage?

The FDA Drug Shortage Database lists 34 of 108 lisdexamfetamine presentations as limited or unavailable (updated October 6, 2026); the first entry was posted on July 14, 2023. 74 more presentations are on the list as available.

Every lisdexamfetamine presentation in the FDA shortage database

Has lisdexamfetamine been recalled?

The FDA's Enforcement Report lists 11 recalls naming lisdexamfetamine since 2016: 0 Class I (the most serious), 10 Class II, 1 Class III; 8 still ongoing. A recall names products and lots, not every product of the medicine.

What does the lisdexamfetamine label say about other medicines?

The lisdexamfetamine label names 8 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.

Check lisdexamfetamine against other medicines

What do FAERS reports show for lisdexamfetamine?

The FDA Adverse Event Reporting System holds 34,602 reports that list lisdexamfetamine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 470 are coded as a death and 4,332 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

Reports received each year

• 3,151
• 1,936
• 1,967
• 1,861
• 1,905
• 1,758
• 2,579
• 3,291
• 3,573
• 3,178
• 1,529

• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

The most reported reactions

• Drug Ineffective (a use or a product term, not a reaction)4,950
• Fatigue2,150
• Off Label Use (a use or a product term, not a reaction)2,115
• Anxiety (named in the label)1,944
• Headache (named in the label)1,857
• Nausea (named in the label)1,642
• Product Availability Issue1,587
• Insomnia (named in the label)1,570

Side effects: the label's list and every FAERS reaction

What else is labeled for the same conditions as lisdexamfetamine?

10 other medicines are given the same way (oral) and in the same FDA class as lisdexamfetamine or labeled mainly for the same use (ADHD), the same class first. ADHD lists all 12 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.

Every medicine labeled for the same conditions as lisdexamfetamine

How does lisdexamfetamine compare with medicines for the same use?

6 side-by-side pages set lisdexamfetamine beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.

• Amphetamine
• Amphetamine and dextroamphetamine
• Atomoxetine
• Dexmethylphenidate
• Dextroamphetamine
• Methylphenidate

What next?

Alternatives to lisdexamfetamine

10 medicines for the same use

Other stimulants

the pharmacologic class, with prices and generics

Lisdexamfetamine side effects

the label's list beside FAERS reports

Lisdexamfetamine shortage record

every presentation, company and date

Check an interaction

what two or more labels say about each other